Edwards Lifesciences stock
Price history
+26.17% over the period1 year: from $84.74 (November 17, 2025) to $106.92 (November 17, 2026), +26.17%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 17, 2026 | $106.92 |
| October 30, 2026 | $92.01 |
| September 30, 2026 | $86.32 |
| August 31, 2026 | $90.75 |
| July 31, 2026 | $86.07 |
| June 30, 2026 | $90.46 |
| May 29, 2026 | $86.47 |
| April 30, 2026 | $83.50 |
| March 31, 2026 | $80.08 |
| February 27, 2026 | $86.47 |
| January 30, 2026 | $81.36 |
| December 31, 2025 | $85.25 |
| November 28, 2025 | $86.67 |
| November 17, 2025 | $84.74 |
At a glance
The company
Develops and distributes heart valve replacement and repair products for minimally invasive and surgical cardiovascular treatments
Latest results
Quarter to September 30, 2026 · EPS $0.80 (estimate $0.74)
TickerLandia's take on Edwards Lifesciences
- Pricier than usual relative to earnings: P/E on the latest fiscal year 58 vs a median of 46 over its last 8 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 62 vs 31 (+96%) in a group of 11.
- Strong point: Financial strength (87/100 in its group). Weak point: Earnings stability (35/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−2.38% from the 52-week high
Analysts · 30 analysts
Average target$113.39+7.55% vs. price
Buy 25 · Hold 4 · Sell 1 · Buy
TickerLandia Fingerprint: Edwards Lifesciences
Compared with similar companies: very high financial strength, very strong momentum, and very high price.
Financials and price compared with 31 companies in the medical devices industry, worldwide. Momentum and risk compared with 883 North American stocks.
Pricevery high82
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 61.6 78 Forward P/E 31.6 88 EV/EBITDA 27.6 88 Price/book 5.68 69 Price/sales 9.23 89 Profitabilityhigh75
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 28.8% 95 Gross margin 78.0% 95 Net margin 15.3% 79 ROA 8.8% 76 ROE 9.3% 31 Earnings stabilitylow35
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 5.3% 15 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 56 Growthhigh63
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) +6.70% 56 Average revenue growth (3 years) +10.77% 69 Revenue growth (year over year) +10.50% 63 Financial strengthvery high87
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −1.24 88 Debt/equitycounts in reverse: lower means more financial strength 0.06 85 Current ratio 4.60 92 Interest coverage 80.3 82 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery strong84
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (6 months) +28.95% 87 1-year return +24.11% 67 Distance from 200-day average +23.88% 92 Relative strength (3 months) +20.40% 91 Risklow24
How much the price swings.
Metric Value Position in group Volatility (60 days) 24.8% 23 Beta (1 year) 0.55 43 Maximum drawdown (12 months) 13.2% 6
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 17, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Edwards Lifesciences is pricier than in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), Edwards Lifesciences's P/E today is 58.4, above the median of its last 8 fiscal years (45.9; between 10.6 and 70.2 from 2018 to 2025). Edwards Lifesciences's P/E (trailing 12 months): 61.6, +96% against the median of a group of 11 similar companies (31.4).
Compared with 11 similar companies
| Metric | Edwards Lifesciences | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 61.6 | High | |
| Forward P/E | 31.6 | High | |
| Operating margin | 28.8% | High | |
| ROE | 9.3% | Low | |
| Debt/equity | 0.06 | Low |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Edwards Lifesciences. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$1.72B
Latest quarter · Q3 2026
Net income
$307.5M
Latest quarter · Q3 2026
Quarterly net margin
17.9%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $61.59B
- P/E
- 61.6
- EPS
- $1.74
- Volume
- 4.05M
- Daily trading
- €447.24M
- Dividend yield
- 0.00%
How Edwards Lifesciences is changing
All resultsRevenue grew 6.7% a year on average over the last 5 years
Operating margin fell from 33.6% to 20.8%
Less cash than profit: free cash flow equal to 34% of net income
Returns
Edwards Lifesciences returns
$1,000 invested in Edwards Lifesciences 5 years ago, on November 17, 2021, would be worth $903 today: −9.66% in total, −2.01% per year. This is the price return only: dividends are excluded.
| Period | Edwards Lifesciences | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +22.59% | −3.17% | $1,226 |
| 6 months | +29.55% | +0.11% | $1,296 |
| Year to date | +25.42% | +8.34% | $1,254 |
| 1 year | +26.17% | +11.15% | $1,262 |
| 3 years | +59.82% | +64.30% | $1,598 |
| 5 years | −9.66% | +58.18% | $903 |
| 10 years | +253.57% | +239.10% | $3,536 |
Over the last 6 months it has done better than 67% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
Edwards Lifesciences: technical analysis
Edwards Lifesciences is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 19.3% below its all-time closing high ($130.68, December 30, 2021).
- Trend
- Upward
- RSI (14 sessions)
- 73
- Above 70: a strong rise in a short time
- vs 200-session average
- +21.78%
Active signals
RSI above 70: the stock has risen a lot in a short time.
since November 4, 2026
Support and resistance
Price areas where Edwards Lifesciences has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price$105.43
- Support$93.43−11.38%2 touches, last on September 1, 2026
- Support$89.59−15.02%2 touches, last on September 16, 2026
- Support$87.97−16.56%7 touches, last on November 2, 2026
Volatility and risk
Over the last year it has moved less than the S&P 500.
- Beta (1 year) vs S&P 500
- 0.54
- Volatility (60 sessions, annualised)
- 25.1%
- Largest fall in the last year
- −13.19%
Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Edwards Lifesciences: seasonality
Average monthly price change over 27 years
Over the last 27 years, the strongest month for Edwards Lifesciences has been December: +4.23% on average, positive in 16 years out of 26. The weakest has been October: −2.49% on average, positive in 14 years out of 27. November, the current month, has been positive in 18 years out of 26 (+3.32% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +1.81% | +1.66% | 15 of 26 |
| February | +1.48% | +1.68% | 15 of 26 |
| March | +2.12% | +1.77% | 19 of 26 |
| April | +3.36% | +4.27% | 18 of 27 |
| May | +2.82% | +2.89% | 19 of 27 |
| June | +3.52% | +4.61% | 18 of 27 |
| July | +0.21% | +1.03% | 15 of 27 |
| August | +1.93% | +1.15% | 18 of 27 |
| September | −1.03% | −2.45% | 10 of 27 |
| October | −2.49% | +0.39% | 14 of 27 |
| November | +3.32% | +3.85% | 18 of 26 |
| December | +4.23% | +3.84% | 16 of 26 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Edwards Lifesciences and its competitors
Edwards Lifesciences sells products and technologies for the treatment of advanced cardiovascular diseases to patients and clinicians in the United States, Europe, Japan and other international markets. Its core offering is transcatheter heart valve therapy, including the SAPIEN valve family for replacing aortic valves without open-heart surgery and the PASCAL and EVOQUE systems for treating mitral and tricuspid valve disease. The company also supplies surgical structural heart products such as the INSPIRIS and INSPIRIS RESILIA aortic valves, the KONECT RESILIA valve conduit and the MITRIS RESILIA valve.
- Headquarters
- Irvine, United States
- Employees
- 16,000
- Founded
- 1958
- Chief executive
- Bernard Zovighian
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Edwards LifesciencesEW | $61.59B | 28.8% | 61.6 | +29.55% |
| Boston ScientificBSX | $63.33B | 19.6% | 18.4 | −18.32% |
| GE HealthCare TechnologiesGEHC | $37B | 13.8% | 17.3 | +34.69% |
| StrykerSYK | $118.29B | 24.0% | 33.1 | +3.51% |
| DexComDXCM | $30.44B | 24.0% | 32.1 | +33.12% |
| MedtronicMDT | $132.22B | 20.1% | 25.4 | +34.37% |
Same industry or related industries, similar size. Compare Edwards Lifesciences with its competitors · Full profile
